Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

Tomoya Yokota, Nobutoshi Ando, Hiroyasu Igaki, Masayuki Shinoda, Ken Kato, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yuukou Kitagawa

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

Original languageEnglish
Pages (from-to)143-151
Number of pages9
JournalOncology (Switzerland)
Volume89
Issue number3
DOIs
Publication statusPublished - 2015 Aug 21

Fingerprint

Esophageal Neoplasms
Fluorouracil
Cisplatin
Drug Therapy
Multivariate Analysis
Esophagectomy
Lymph Node Excision
Serum Albumin
Esophagus
Squamous Cell Carcinoma
Therapeutics

Keywords

  • Clinical T stage
  • Esophageal squamous cell carcinoma
  • Neoadjuvant chemotherapy
  • Pathological findings
  • Prognostic factors
  • Serum albumin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). / Yokota, Tomoya; Ando, Nobutoshi; Igaki, Hiroyasu; Shinoda, Masayuki; Kato, Ken; Mizusawa, Junki; Katayama, Hiroshi; Nakamura, Kenichi; Fukuda, Haruhiko; Kitagawa, Yuukou.

In: Oncology (Switzerland), Vol. 89, No. 3, 21.08.2015, p. 143-151.

Research output: Contribution to journalArticle

Yokota, T, Ando, N, Igaki, H, Shinoda, M, Kato, K, Mizusawa, J, Katayama, H, Nakamura, K, Fukuda, H & Kitagawa, Y 2015, 'Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)', Oncology (Switzerland), vol. 89, no. 3, pp. 143-151. https://doi.org/10.1159/000381065
Yokota, Tomoya ; Ando, Nobutoshi ; Igaki, Hiroyasu ; Shinoda, Masayuki ; Kato, Ken ; Mizusawa, Junki ; Katayama, Hiroshi ; Nakamura, Kenichi ; Fukuda, Haruhiko ; Kitagawa, Yuukou. / Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). In: Oncology (Switzerland). 2015 ; Vol. 89, No. 3. pp. 143-151.
@article{0c8c939da86b45c1a6b5a6644cc62ab4,
title = "Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)",
abstract = "Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)",
keywords = "Clinical T stage, Esophageal squamous cell carcinoma, Neoadjuvant chemotherapy, Pathological findings, Prognostic factors, Serum albumin",
author = "Tomoya Yokota and Nobutoshi Ando and Hiroyasu Igaki and Masayuki Shinoda and Ken Kato and Junki Mizusawa and Hiroshi Katayama and Kenichi Nakamura and Haruhiko Fukuda and Yuukou Kitagawa",
year = "2015",
month = "8",
day = "21",
doi = "10.1159/000381065",
language = "English",
volume = "89",
pages = "143--151",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

AU - Yokota, Tomoya

AU - Ando, Nobutoshi

AU - Igaki, Hiroyasu

AU - Shinoda, Masayuki

AU - Kato, Ken

AU - Mizusawa, Junki

AU - Katayama, Hiroshi

AU - Nakamura, Kenichi

AU - Fukuda, Haruhiko

AU - Kitagawa, Yuukou

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

AB - Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

KW - Clinical T stage

KW - Esophageal squamous cell carcinoma

KW - Neoadjuvant chemotherapy

KW - Pathological findings

KW - Prognostic factors

KW - Serum albumin

UR - http://www.scopus.com/inward/record.url?scp=84942196741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942196741&partnerID=8YFLogxK

U2 - 10.1159/000381065

DO - 10.1159/000381065

M3 - Article

VL - 89

SP - 143

EP - 151

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 3

ER -